[{"id":"169efeb8-decd-470a-9a13-85504fe81ffc","acronym":"RAMTAS","url":"https://clinicaltrials.gov/study/NCT03520946","created_at":"2021-01-18T17:20:13.299Z","updated_at":"2024-07-02T16:35:53.570Z","phase":"Phase 3","brief_title":"RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT03520946 - RAMTAS","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF mutation + RAS mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF mutation + RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-03-10"}]